Natera and Eledon Pharmaceuticals partnered to incorporate Prospera, Natera’s donor-derived cell-free DNA test, as the exclusive dd-cfDNA monitoring assay in Eledon’s planned Phase III kidney transplant trial of tegoprubart. The study is expected to enroll about 600 recipients across more than 100 transplant centers. Prospera will be used for longitudinal monitoring under a two-threshold algorithm that evaluates both relative dd-cfDNA fraction and absolute dd-cfDNA amount. Eledon’s tegoprubart is an investigational anti-CD40L antibody intended to prevent organ rejection with an eye toward reducing toxicity burdens associated with standard long-term immunosuppression. Natera said this would be the first time Prospera is embedded as a longitudinal surveillance tool in a large-scale therapeutic trial in transplantation. Why it matters: dd-cfDNA monitoring can influence clinical decision-making and endpoint interpretation in transplant trials, potentially improving how outcomes are linked to graft injury dynamics.